HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUNEONCO-B

13.990

-1.010-6.73%

Volume:14.36M

Turnover:187.37M

Market Cap:5.70B

PE:-15.28

High:14.200

Open:14.140

Low:11.910

Close:15.000

52wk High:15.680

52wk Low:3.210

Shares:407.31M

HK Float Shares:396.28M

Volume Ratio:2.53

T/O Rate:3.62%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.916

ROE:-53.53%

ROA:-25.66%

PB:9.75

PE(LYR):-15.28

PS:42.43

Loading ...

Overview Company News Filings

Hong Kong Stock Alert | IMMUNEONCO-B (01541) Surges Over 10% on Positive Clinical Trial Progress, Maintains "Buy" Rating

ImmuneOnco Biopharmaceuticals' Loss Narrows in H1

MT Newswires Live

IMMUNEONCO-B (01541) Reports Interim Results with Revenue of RMB 38.027 Million, Surging 49,285.71% Year-over-Year

ImmuneOnco Biopharmaceuticals Doses First Patient in IMC-003/IMM72 Study; Shares Slip 4%

MT Newswires Live

IMMUNEONCO-B (01541): First Patient Successfully Dosed in Phase 1 Clinical Trial of IMC-003/IMM72

ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S

ImmuneOnco Biopharmaceuticals Says No Undisclosed Matter That Warrants Stock Price Movement; Shares Fall 13%

MT Newswires Live

ImmuneOnco's Licensee Gets US FDA's Clearance to Trial Tumor Drug

MT Newswires Live

BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Clearance Of Ind Application For Imm2510/Axn-2510 By FDA

Immuneonco Biopharmaceuticals Announces New Appointments to Nomination Committee, Enhancing Board Diversity and Corporate Governance

Immuneonco Biopharmaceuticals Secures NMPA Approval for Clinical Trial of IMC-003/IMM72 for PAH Treatment

BRIEF-Immuneonco Biopharmaceuticals Shanghai Gives Notice To Haitong ASM To Redeem HK$200 Million Product

ImmuneOnco Biopharmaceuticals Appoints Dr. Wu Zhuli as Chief Medical Officer

HK Movers | Biopharmaceutical Stocks Jump With SinoMab BioScience up 18%

Tiger Newspress

ImmuneOnco Biopharmaceuticals Pledges Compliance After Disclosure Lapse

MT Newswires Live

Instil Bio Announces Upcoming Phase 3 Trial of '2510 in Combination with Chemotherapy for First-Line NSCLC in China, Set to Begin Mid-2026

ADVISORY-Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn

Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment

ImmuneOnco Biopharmaceuticals Completes H Share Full Circulation

MT Newswires Live

Immuneonco Biopharmaceuticals Files Disclosure to HKEX: Increases Share Capital with 14,114,006 New Shares, Price Not Specified

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/01541/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01541","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"IMMUNEONCO-B","latestPrice":13.99,"timestamp":1757405293000,"preClose":15,"halted":0,"volume":14363800,"delay":0,"floatShares":396277305,"shares":407307695,"eps":-0.9156798977755969,"marketStatus":"Not Yet Opened","change":-1.01,"latestTime":"09-09 16:08:13","open":14.14,"high":14.2,"low":11.91,"amount":187371074,"amplitude":0.152667,"askPrice":13.99,"askSize":44000,"bidPrice":13.97,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-0.8405474517500817,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":15,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"volumeRatio":2.5280902831868333,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","floatShares":396277305,"roa":"-25.66%","roe":"-53.53%","lyrEps":-0.91568,"volumeRatio":2.5280902831868333,"shares":407307695,"dividePrice":0,"high":14.2,"amplitude":0.152667,"preClose":15,"low":11.91,"week52Low":3.21,"pbRate":"9.75","psRate":"42.43","week52High":15.68,"institutionHeld":0,"latestPrice":13.99,"committee":-0.964286,"eps":-0.9156798977755969,"divideRate":0,"volume":14363800,"delay":0,"ttmEps":-0.8405474517500817,"open":14.14,"prevYearClose":5.16,"prevWeekClose":13.98,"prevMonthClose":10.9,"prevQuarterClose":12,"fiveDayClose":11.01,"twentyDayClose":11.1,"sixtyDayClose":13.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01541\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null},{"date":"2025-03-25","symbol":"01541","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742866200000,"name":null,"time":"Post Market","dateTimestamp":1742832000000,"actualEps":null},{"market":"HK","date":"2024-08-26","symbol":"01541","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1724601600000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01541\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01541\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1697558400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01541\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01541","date":"2025-09-08","current":-18.467104,"percent":0.237425,"low":-30.003263,"twenty":-22.24223,"median":-13.03944,"eighty":-6.076947,"high":-2.993766,"avg":-13.643508,"sd":7.593686,"marketCap":6109615425},"quantilePoints":[{"date":"2023-08-31","current":-17.746094,"twenty":-17.746094,"median":-17.746094,"eighty":-17.746094,"marketCap":6942262047},{"date":"2023-09-08","current":-19.116691,"twenty":-19.083294,"median":-18.655615,"eighty":-17.801139,"marketCap":7390149921},{"date":"2023-09-15","current":-24.765877,"twenty":-24.765877,"median":-19.116691,"eighty":-18.557812,"marketCap":9648251285},{"date":"2023-09-22","current":-25.548224,"twenty":-25.200205,"median":-24.360534,"eighty":-18.753419,"marketCap":9909519212},{"date":"2023-09-29","current":-29.804324,"twenty":-26.447668,"median":-24.870232,"eighty":-19.083294,"marketCap":11580180660},{"date":"2023-10-06","current":-24.76052,"twenty":-26.458287,"median":-24.870232,"eighty":-19.110012,"marketCap":9615852761},{"date":"2023-10-13","current":-27.113287,"twenty":-26.458287,"median":-25.206314,"eighty":-22.322253,"marketCap":10513831229},{"date":"2023-10-20","current":-26.768577,"twenty":-26.795293,"median":-25.37532,"eighty":-23.788881,"marketCap":10364168151},{"date":"2023-10-27","current":-28.665306,"twenty":-27.124745,"median":-25.753577,"eighty":-24.00727,"marketCap":11093775656},{"date":"2023-11-03","current":-26.275244,"twenty":-27.500238,"median":-26.158488,"eighty":-24.473108,"marketCap":10195797188},{"date":"2023-11-10","current":-26.039628,"twenty":-27.37617,"median":-26.041732,"eighty":-24.763734,"marketCap":10102257765},{"date":"2023-11-17","current":-26.714897,"twenty":-27.225983,"median":-26.171076,"eighty":-24.792429,"marketCap":10457707575},{"date":"2023-11-24","current":-27.539565,"twenty":-27.37617,"median":-26.271304,"eighty":-24.846191,"marketCap":10869281039},{"date":"2023-12-01","current":-28.464343,"twenty":-27.564693,"median":-26.306056,"eighty":-24.874164,"marketCap":11280854504},{"date":"2023-12-08","current":-27.67933,"twenty":-27.70336,"median":-26.447668,"eighty":-25.070837,"marketCap":10925404694},{"date":"2023-12-15","current":-27.708906,"twenty":-27.817253,"median":-26.526325,"eighty":-25.207536,"marketCap":11000236233},{"date":"2023-12-22","current":-27.916049,"twenty":-27.937914,"median":-26.714897,"eighty":-25.244891,"marketCap":11075067772},{"date":"2023-12-29","current":-28.049426,"twenty":-27.986303,"median":-26.835368,"eighty":-25.288293,"marketCap":11187315080},{"date":"2024-01-05","current":-23.146888,"twenty":-27.970711,"median":-26.68937,"eighty":-25.200205,"marketCap":9166863527},{"date":"2024-01-12","current":-26.439512,"twenty":-27.935571,"median":-26.500765,"eighty":-25.200205,"marketCap":10476415460},{"date":"2024-01-19","current":-25.435754,"twenty":-27.916049,"median":-26.490281,"eighty":-25.212424,"marketCap":10064841995},{"date":"2024-01-26","current":-23.636611,"twenty":-27.83997,"median":-26.442842,"eighty":-24.972615,"marketCap":9316526605},{"date":"2024-02-02","current":-21.195554,"twenty":-27.817533,"median":-26.372788,"eighty":-24.783518,"marketCap":8343716598},{"date":"2024-02-09","current":-18.727145,"twenty":-27.802108,"median":-26.275244,"eighty":-24.041989,"marketCap":7408322361},{"date":"2024-02-16","current":-17.739662,"twenty":-27.801452,"median":-26.252628,"eighty":-23.794995,"marketCap":7019198358},{"date":"2024-02-23","current":-22.387155,"twenty":-27.764049,"median":-26.165159,"eighty":-23.13759,"marketCap":8811413717},{"date":"2024-03-01","current":-17.708555,"twenty":-27.735275,"median":-26.04068,"eighty":-22.460898,"marketCap":6974299434},{"date":"2024-03-08","current":-19.229551,"twenty":-27.718352,"median":-26.025076,"eighty":-21.141323,"marketCap":7576693323},{"date":"2024-03-15","current":-16.157629,"twenty":-27.69116,"median":-25.695795,"eighty":-19.998834,"marketCap":6360680815},{"date":"2024-03-22","current":-15.411367,"twenty":-27.66021,"median":-25.548224,"eighty":-19.057216,"marketCap":6061354659},{"date":"2024-03-28","current":-14.696214,"twenty":-27.629432,"median":-25.408294,"eighty":-18.737655,"marketCap":6038905197},{"date":"2024-04-05","current":-13.011166,"twenty":-27.602384,"median":-25.364375,"eighty":-18.557812,"marketCap":5342971884},{"date":"2024-04-12","current":-13.094845,"twenty":-27.539565,"median":-25.225009,"eighty":-18.239836,"marketCap":5380387654},{"date":"2024-04-19","current":-13.014894,"twenty":-27.51439,"median":-25.154554,"eighty":-17.708555,"marketCap":5342971884},{"date":"2024-04-26","current":-13.779237,"twenty":-27.443648,"median":-24.972615,"eighty":-16.602696,"marketCap":5649781194},{"date":"2024-05-03","current":-12.839078,"twenty":-27.434442,"median":-24.870232,"eighty":-16.184677,"marketCap":5260657191},{"date":"2024-05-10","current":-13.282389,"twenty":-27.357513,"median":-24.774698,"eighty":-14.702373,"marketCap":5455219193},{"date":"2024-05-17","current":-13.228926,"twenty":-27.225983,"median":-24.581805,"eighty":-14.243189,"marketCap":5425286577},{"date":"2024-05-24","current":-13.350651,"twenty":-27.145452,"median":-23.955191,"eighty":-13.966896,"marketCap":5462702347},{"date":"2024-05-31","current":-13.410156,"twenty":-27.124745,"median":-23.750163,"eighty":-13.747349,"marketCap":5492634962},{"date":"2024-06-07","current":-14.158514,"twenty":-27.039336,"median":-23.288627,"eighty":-13.645876,"marketCap":5791961118},{"date":"2024-06-14","current":-13.347574,"twenty":-26.971042,"median":-23.123643,"eighty":-13.527845,"marketCap":5455219193},{"date":"2024-06-21","current":-13.283836,"twenty":-26.926395,"median":-22.448608,"eighty":-13.452996,"marketCap":5417803423},{"date":"2024-06-28","current":-12.683619,"twenty":-26.848726,"median":-21.974147,"eighty":-13.40419,"marketCap":5170859344},{"date":"2024-07-05","current":-11.291057,"twenty":-26.759122,"median":-21.059976,"eighty":-13.359292,"marketCap":4602139648},{"date":"2024-07-12","current":-12.246119,"twenty":-26.720023,"median":-20.206581,"eighty":-13.323498,"marketCap":4998746805},{"date":"2024-07-19","current":-11.915911,"twenty":-26.704686,"median":-19.229551,"eighty":-13.282563,"marketCap":4864050035},{"date":"2024-07-26","current":-11.780484,"twenty":-26.652155,"median":-19.050696,"eighty":-13.224977,"marketCap":4826634265},{"date":"2024-08-02","current":-13.633124,"twenty":-26.594701,"median":-18.753419,"eighty":-13.20236,"marketCap":5582432809},{"date":"2024-08-09","current":-9.567144,"twenty":-26.54166,"median":-18.630761,"eighty":-13.102374,"marketCap":3943622105},{"date":"2024-08-16","current":-8.483685,"twenty":-26.496571,"median":-18.451463,"eighty":-13.086665,"marketCap":3498374448},{"date":"2024-08-23","current":-8.095604,"twenty":-26.47337,"median":-18.020488,"eighty":-13.035717,"marketCap":3352452947},{"date":"2024-08-30","current":-7.377309,"twenty":-26.446703,"median":-17.739662,"eighty":-12.990136,"marketCap":3034418906},{"date":"2024-09-06","current":-4.227864,"twenty":-26.442176,"median":-17.681919,"eighty":-12.840212,"marketCap":1739833281},{"date":"2024-09-13","current":-4.503325,"twenty":-26.43833,"median":-16.602696,"eighty":-12.741292,"marketCap":1848339013},{"date":"2024-09-20","current":-4.539912,"twenty":-26.433601,"median":-16.202037,"eighty":-12.246119,"marketCap":1874530051},{"date":"2024-09-27","current":-5.476578,"twenty":-26.311976,"median":-15.844451,"eighty":-11.915911,"marketCap":2274878785},{"date":"2024-10-04","current":-6.596451,"twenty":-26.302504,"median":-15.05764,"eighty":-11.832338,"marketCap":2727609596},{"date":"2024-10-10","current":-5.983695,"twenty":-26.285201,"median":-14.496802,"eighty":-11.807116,"marketCap":2458216056},{"date":"2024-10-18","current":-5.191078,"twenty":-26.27288,"median":-14.209972,"eighty":-11.719903,"marketCap":2121474130},{"date":"2024-10-25","current":-7.104995,"twenty":-26.248892,"median":-14.119017,"eighty":-11.287262,"marketCap":2903463713},{"date":"2024-11-01","current":-6.615271,"twenty":-26.199776,"median":-13.881638,"eighty":-9.764235,"marketCap":2705160134},{"date":"2024-11-08","current":-6.847628,"twenty":-26.169892,"median":-13.803075,"eighty":-8.441853,"marketCap":2787474827},{"date":"2024-11-15","current":-7.078843,"twenty":-26.118271,"median":-13.690467,"eighty":-8.248986,"marketCap":2851081635},{"date":"2024-11-22","current":-6.784782,"twenty":-26.059844,"median":-13.633178,"eighty":-7.853303,"marketCap":2731351173},{"date":"2024-11-29","current":-5.682581,"twenty":-26.04047,"median":-13.539989,"eighty":-7.45767,"marketCap":2286103516},{"date":"2024-12-06","current":-5.602773,"twenty":-26.037499,"median":-13.514674,"eighty":-7.358253,"marketCap":2248687746},{"date":"2024-12-13","current":-6.121403,"twenty":-26.029477,"median":-13.45004,"eighty":-7.218028,"marketCap":2451992323},{"date":"2024-12-20","current":-5.137492,"twenty":-25.962318,"median":-13.411134,"eighty":-7.087735,"marketCap":2048757705},{"date":"2024-12-27","current":-4.957491,"twenty":-25.887099,"median":-13.400213,"eighty":-7.078006,"marketCap":1975442320},{"date":"2025-01-03","current":-5.238569,"twenty":-25.753577,"median":-13.368079,"eighty":-6.925822,"marketCap":2089488475},{"date":"2025-01-10","current":-5.002231,"twenty":-25.638014,"median":-13.3526,"eighty":-6.765934,"marketCap":1987661551},{"date":"2025-01-17","current":-5.018682,"twenty":-25.5579,"median":-13.317479,"eighty":-6.665777,"marketCap":1995807705},{"date":"2025-01-24","current":-5.323319,"twenty":-25.548224,"median":-13.283546,"eighty":-6.596451,"marketCap":2130219244},{"date":"2025-01-28","current":-5.224689,"twenty":-25.503236,"median":-13.282823,"eighty":-6.532117,"marketCap":2101707706},{"date":"2025-02-07","current":-5.549725,"twenty":-25.42477,"median":-13.246663,"eighty":-6.254752,"marketCap":2219826937},{"date":"2025-02-14","current":-5.930475,"twenty":-25.395104,"median":-13.220128,"eighty":-6.076947,"marketCap":2366457707},{"date":"2025-02-21","current":-6.375256,"twenty":-25.366564,"median":-13.201126,"eighty":-6.054191,"marketCap":2557892324},{"date":"2025-02-28","current":-5.632443,"twenty":-25.318672,"median":-13.116805,"eighty":-5.974648,"marketCap":2252411553},{"date":"2025-03-07","current":-5.782376,"twenty":-25.249925,"median":-13.099044,"eighty":-5.827424,"marketCap":2321653861},{"date":"2025-03-14","current":-4.421401,"twenty":-25.219975,"median":-13.087912,"eighty":-5.725677,"marketCap":1775861550},{"date":"2025-03-21","current":-4.778207,"twenty":-25.207536,"median":-13.071662,"eighty":-5.66584,"marketCap":1918419243},{"date":"2025-03-28","current":-6.735516,"twenty":-25.163684,"median":-13.026305,"eighty":-5.651503,"marketCap":2276850015},{"date":"2025-04-03","current":-7.956153,"twenty":-25.0977,"median":-13.01303,"eighty":-5.66026,"marketCap":2684157710},{"date":"2025-04-11","current":-6.344288,"twenty":-25.036833,"median":-12.972072,"eighty":-5.68428,"marketCap":2126146167},{"date":"2025-04-17","current":-6.122985,"twenty":-24.972615,"median":-12.844749,"eighty":-5.691075,"marketCap":2056903859},{"date":"2025-04-25","current":-8.576896,"twenty":-24.895951,"median":-12.836736,"eighty":-5.703559,"marketCap":2883738480},{"date":"2025-05-02","current":-7.700417,"twenty":-24.872853,"median":-12.82514,"eighty":-5.710649,"marketCap":2594550017},{"date":"2025-05-09","current":-7.730765,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"marketCap":2623061555},{"date":"2025-05-16","current":-8.311097,"twenty":-24.799485,"median":-12.12195,"eighty":-5.751942,"marketCap":2843007711},{"date":"2025-05-23","current":-11.289802,"twenty":-24.776462,"median":-11.940532,"eighty":-5.771038,"marketCap":3873496179},{"date":"2025-05-30","current":-15.223569,"twenty":-24.763734,"median":-11.970101,"eighty":-5.797425,"marketCap":5246123111},{"date":"2025-06-06","current":-16.623143,"twenty":-24.617548,"median":-12.331836,"eighty":-5.827424,"marketCap":5743038499},{"date":"2025-06-13","current":-15.603079,"twenty":-24.258649,"median":-12.701975,"eighty":-5.862056,"marketCap":5392753881},{"date":"2025-06-20","current":-14.878015,"twenty":-24.00727,"median":-12.82804,"eighty":-5.90109,"marketCap":5132076957},{"date":"2025-06-27","current":-13.023121,"twenty":-23.933348,"median":-12.837907,"eighty":-5.91626,"marketCap":4504823106},{"date":"2025-07-04","current":-14.906416,"twenty":-23.89321,"median":-12.895238,"eighty":-5.935244,"marketCap":5156515418},{"date":"2025-07-11","current":-12.022018,"twenty":-23.818294,"median":-12.972072,"eighty":-5.957179,"marketCap":4154538489},{"date":"2025-07-18","current":-12.975089,"twenty":-23.597552,"median":-12.895238,"eighty":-5.971632,"marketCap":4480384645},{"date":"2025-07-25","current":-12.316929,"twenty":-23.410778,"median":-12.839078,"eighty":-5.984465,"marketCap":4268584643},{"date":"2025-08-01","current":-12.109688,"twenty":-23.260279,"median":-12.895238,"eighty":-5.992729,"marketCap":4170830796},{"date":"2025-08-08","current":-13.046774,"twenty":-23.142239,"median":-12.972072,"eighty":-6.013995,"marketCap":4504823106},{"date":"2025-08-15","current":-15.594562,"twenty":-23.052783,"median":-12.982136,"eighty":-6.023266,"marketCap":5376461574},{"date":"2025-08-22","current":-14.245172,"twenty":-22.717488,"median":-13.011166,"eighty":-6.052989,"marketCap":4895838493},{"date":"2025-08-29","current":-13.416028,"twenty":-22.485479,"median":-13.022379,"eighty":-6.061027,"marketCap":4439653875},{"date":"2025-09-05","current":-17.224047,"twenty":-22.314693,"median":-13.032106,"eighty":-6.075447,"marketCap":5694161576},{"date":"2025-09-08","current":-18.467104,"twenty":-22.24223,"median":-13.03944,"eighty":-6.076947,"marketCap":6109615425}],"updateTime":1757457782476},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01541\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1150921357","title":"Hong Kong Stock Alert | IMMUNEONCO-B (01541) Surges Over 10% on Positive Clinical Trial Progress, Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1150921357","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150921357?lang=en_us&edition=fundamental","pubTime":"2025-09-05 13:44","pubTimestamp":1757051056,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) surged over 10% today. As of press time, the stock was up 13.82% to HK$14, with trading turnover reaching HK$82.22 million. On the news front, IMMUNEONCO released its interim...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2562796809","title":"ImmuneOnco Biopharmaceuticals' Loss Narrows in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2562796809","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562796809?lang=en_us&edition=fundamental","pubTime":"2025-08-27 12:22","pubTimestamp":1756268520,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  booked a loss attributable to owners of 152.6 million yuan for the first half of 2025, narrower than a loss of 165.8 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.Shares of the pharmaceutical firm gained over 2% in Wednesday morning trade.Loss per share came in at 0.37 yuan, compared with 0.44 yuan in the prior-year period.Revenue surged to 38 million yuan from 77,000 yuan.The board declared no dividend.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1197406454","title":"IMMUNEONCO-B (01541) Reports Interim Results with Revenue of RMB 38.027 Million, Surging 49,285.71% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1197406454","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197406454?lang=en_us&edition=fundamental","pubTime":"2025-08-26 21:26","pubTimestamp":1756214794,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 38.027 million, representing a substantial increase of 49,285.71% compared to the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2560168328","title":"ImmuneOnco Biopharmaceuticals Doses First Patient in IMC-003/IMM72 Study; Shares Slip 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560168328","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560168328?lang=en_us&edition=fundamental","pubTime":"2025-08-19 14:43","pubTimestamp":1755585839,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) successfully dosed the first patient in a phase I clinical trial of IMC-003/IMM72, a late Monday Hong Kong bourse filing said.Shares of the pharma company were down nearly 4% in Tuesday afternoon trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1139172125","title":"IMMUNEONCO-B (01541): First Patient Successfully Dosed in Phase 1 Clinical Trial of IMC-003/IMM72","url":"https://stock-news.laohu8.com/highlight/detail?id=1139172125","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139172125?lang=en_us&edition=fundamental","pubTime":"2025-08-18 22:42","pubTimestamp":1755528138,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced that the first patient in the Phase 1 clinical trial of IMC-003/IMM72 has been successfully dosed, marking a significant milestone in the group's clinical research of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2555593046","title":"ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S","url":"https://stock-news.laohu8.com/highlight/detail?id=2555593046","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555593046?lang=en_us&edition=fundamental","pubTime":"2025-07-30 19:37","pubTimestamp":1753875436,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration . IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL3Gr3D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK1161","TIL","BK4139","01541"],"gpt_icon":0},{"id":"2550006766","title":"ImmuneOnco Biopharmaceuticals Says No Undisclosed Matter That Warrants Stock Price Movement; Shares Fall 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550006766","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550006766?lang=en_us&edition=fundamental","pubTime":"2025-07-11 13:15","pubTimestamp":1752210910,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   said there were no undisclosed matters that would warrant an unusual movement in its stock price, according to a Hong Kong filing Friday.Shares declined over 13% in recent afternoon trade.The pharma company said it had taken notice of the recent unusual fluctuations in its stock price even though its operations and clinical development remained \"normal.\"Meanwhile, there were no material adverse changes to the company's financial position, ImmuneOnco Biopharmaceuticals said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2548492899","title":"ImmuneOnco's Licensee Gets US FDA's Clearance to Trial Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2548492899","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548492899?lang=en_us&edition=fundamental","pubTime":"2025-07-02 19:28","pubTimestamp":1751455703,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said licensee Instil Bio obtained investigational new drug clearance for IMM2510/AXN-2510 from the US Food and Drug Administration (FDA), a Wednesda","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2548893294","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Clearance Of Ind Application For Imm2510/Axn-2510 By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2548893294","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548893294?lang=en_us&edition=fundamental","pubTime":"2025-07-02 18:24","pubTimestamp":1751451865,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Clearance Of Ind Application For Imm2510/Axn-2510 By FDAJuly 2  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:CLEARANCE OF IND APPLICATION FOR IMM2510/AXN-2510 BY U.S. FDAFurther company coverage: 1541.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nFWN3SZ0BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2548701643","title":"Immuneonco Biopharmaceuticals Announces New Appointments to Nomination Committee, Enhancing Board Diversity and Corporate Governance","url":"https://stock-news.laohu8.com/highlight/detail?id=2548701643","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548701643?lang=en_us&edition=fundamental","pubTime":"2025-07-01 00:02","pubTimestamp":1751299345,"startTime":"0","endTime":"0","summary":"Immuneonco Biopharmaceuticals Announces New Appointments to Nomination Committee, Enhancing Board Diversity and Corporate Governance. ImmuneOnco Biopharmaceuticals  Inc. has announced changes to its Nomination Committee, effective June 30, 2025. Ms. Fu Dawei and Dr. Kendall Arthur Smith have been appointed as new members. The committee now comprises one executive Director, one non-executive Director, and three independent non-executive Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLhZJBc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2545456829","title":"Immuneonco Biopharmaceuticals Secures NMPA Approval for Clinical Trial of IMC-003/IMM72 for PAH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2545456829","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545456829?lang=en_us&edition=fundamental","pubTime":"2025-06-23 06:07","pubTimestamp":1750630056,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. has announced that it has received approval from the National Medical Products Administration  of the People's Republic of China to initiate a clinical trial for their investigational new drug, IMC-003/IMM72. The trial aims to explore the treatment of pulmonary arterial hypertension  using this new generation activin receptor type IIA-Fc  fusion protein, which has been enhanced through genetic engineering for improved activity and quality attributes. ImmuneOnco Biopharmaceuticals holds the global intellectual property rights and development and commercialization rights for IMC-003/IMM72. This approval marks a significant milestone in the company's ongoing efforts to advance its biopharmaceutical innovations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should no","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nNDL8gFhPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2543606776","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Gives Notice To Haitong ASM To Redeem HK$200 Million Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2543606776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543606776?lang=en_us&edition=fundamental","pubTime":"2025-06-16 23:03","pubTimestamp":1750086189,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Gives Notice To Haitong ASM To Redeem HK$200 Million ProductJune 16  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:GIVEN NOTICE TO HAITONG ASM TO REDEEM HK$200 MILLION OF HAITONG PRODUCT ON JUNE 16, 2025Further company coverage: 1541.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nFWN3SJ0HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2542798809","title":"ImmuneOnco Biopharmaceuticals Appoints Dr. Wu Zhuli as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2542798809","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542798809?lang=en_us&edition=fundamental","pubTime":"2025-06-09 16:32","pubTimestamp":1749457945,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Inc. has announced the appointment of Dr. Wu Zhuli as Chief Medical Officer, effective June 9, 2025. Dr. Wu, who has over 13 years of experience in clinical drug development in hematology, oncology, and immunology, will oversee the establishment and management of the Company's clinical team and research efforts. She previously held positions at Janssen Pharmaceuticals, Roche, and Shanghai Fosun Pharmaceutical. Dr. Wu will report directly to Dr. Tian Wenzhi, the founder and Chairman of the Company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDLl1CnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","IE00BVYPNV92.GBP","LU1778281490.HKD","LU1718418525.SGD","SG9999002232.USD","LU1061106388.HKD","IE00B3PB1722.GBP","LU1935042991.SGD","IE00B7SZLL34.SGD","IE0034235303.USD","BK0012","IE00B3T34201.USD","LU1244550577.SGD","LU0889566641.SGD","IE00BLSP4239.USD","BK0183","LU1059921491.USD","LU1267930813.SGD","LU2592432038.USD","SG9999001440.SGD","BK0196","BK4588","BK0239","LU1074936037.SGD","LU1674673428.USD","LU2505996509.AUD","LU1032955483.USD","BK0187","IE00BSNM7G36.USD","LU1066051498.USD","01541","LU1244550221.USD","BK0175","LU1032466523.USD","BK0028","BK0188","LU0289739699.SGD","IE00BFXG1179.USD","LU0320765646.SGD","BK4007","LU1732800096.USD","LU2133065610.SGD","LU1732799900.SGD","600196","IE00B1BXHZ80.USD","LU0792757196.USD","LU0345769631.USD","00656","LU0640476718.USD","JNJ"],"gpt_icon":0},{"id":"1156294759","title":"HK Movers |  Biopharmaceutical Stocks Jump With SinoMab BioScience up 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156294759","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156294759?lang=en_us&edition=fundamental","pubTime":"2025-05-30 11:06","pubTimestamp":1748574369,"startTime":"0","endTime":"0","summary":"Hong Kong-listed biopharmaceutical stocks surged again, with SinoMab BioScience soaring 18%, ImmuneOnco climbing 16%, and Ascletis Pharma rising over 12%. Abbisko, Jacobio Pharm, and HBM Holdings all gained about 4%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8a007331050a4c5abbca4a26fc55f3d6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","02256","03681","01541","02142","01672"],"gpt_icon":0},{"id":"2538443204","title":"ImmuneOnco Biopharmaceuticals Pledges Compliance After Disclosure Lapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2538443204","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538443204?lang=en_us&edition=fundamental","pubTime":"2025-05-28 15:11","pubTimestamp":1748416285,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   has taken remedial actions after it failed to inform the Hong Kong bourse regarding the extension of the subscription of certain wealth management products, a Tuesday Hong Kong bourse filing said.The issue arose as the company considered an extension in the subscription as an immaterial modification instead of a new subscription under the bourse's listing rules.The firm conducted a detailed review of its wealth management product subscription, pledged to comply with information disclosure requirements, and decided to provide training to the relevant individuals among other measures.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2538492592","title":"Instil Bio Announces Upcoming Phase 3 Trial of '2510 in Combination with Chemotherapy for First-Line NSCLC in China, Set to Begin Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2538492592","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538492592?lang=en_us&edition=fundamental","pubTime":"2025-05-28 05:04","pubTimestamp":1748379862,"startTime":"0","endTime":"0","summary":"Instil Bio Announces Upcoming Phase 3 Trial of '2510 in Combination with Chemotherapy for First-Line NSCLC in China, Set to Begin Mid-2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Instil Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL5d7SRW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","TIL","01541","BK4139","BK4505"],"gpt_icon":0},{"id":"2537917708","title":"ADVISORY-Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2537917708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537917708?lang=en_us&edition=fundamental","pubTime":"2025-05-22 18:29","pubTimestamp":1747909793,"startTime":"0","endTime":"0","summary":"ADVISORY-Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawnAlerts on Instil Bio TIL.O and ImmuneOnco Biopharmaceuticals 1541.HK announcing clinical trial updates for Phase 2 tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nFWN3RU0PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4505","01541","TIL","BK4139"],"gpt_icon":0},{"id":"2537854917","title":"Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537854917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537854917?lang=en_us&edition=fundamental","pubTime":"2025-05-22 18:09","pubTimestamp":1747908578,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer . The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with Instil Bio, Inc., is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL1NChjy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161","BK4505","TIL","BK4139"],"gpt_icon":0},{"id":"2535258290","title":"ImmuneOnco Biopharmaceuticals Completes H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2535258290","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535258290?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:53","pubTimestamp":1747223597,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) completed the conversion of 14,114,006 unlisted shares into H shares on Wednesday, a same-day Hong Kong bourse filing said.Listing of the converted H shares on the Hong Kong stock exchange will begin at 9:00 am on Thursday, May 15.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2535493250","title":"Immuneonco Biopharmaceuticals Files Disclosure to HKEX: Increases Share Capital with 14,114,006 New Shares, Price Not Specified","url":"https://stock-news.laohu8.com/highlight/detail?id=2535493250","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535493250?lang=en_us&edition=fundamental","pubTime":"2025-05-14 18:25","pubTimestamp":1747218302,"startTime":"0","endTime":"0","summary":"Immuneonco Biopharmaceuticals Files Disclosure to HKEX: Increases Share Capital with 14,114,006 New Shares, Price Not Specified. Immuneonco Biopharmaceuticals  Co. Ltd. has filed a next day disclosure return to the Hong Kong Stock Exchange, announcing the conversion of 14,114,006 unlisted shares into H shares, resulting in a 3.47% increase in the number of issued shares. This change brings the total number of issued shares to 396,277,305 as of May 14, 2025. The issue price per share was not disclosed in the document.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information containe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL6YTnNg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}